Regardless of family history, screening represents one of the most promising approaches to reduce cancer burden through early detection and treatment. 7, 8 Screening tests for colorectal cancer are effective in decreasing the incidence of new disease through the detection and removal of precancerous lesions and in improving survival through early detection and treatment. 9 -18 Thus, screening utilization can have considerable impact on population-level cancer incidence and mortality.
Patterns of screening can also have broader, more complicated implications on patterns of disease if screening uptake depends on a personal risk factor such as family history. Colorectal screening utilization is almost doubled among those with a family history of colorectal cancer. 19 Because screening can detect precursor lesions and may result in removal of such lesions before they become invasive, persons with a family history could experience lower incidence rates than the general population simply due to greater use of screening. 20 The consequences of such an altered association between family history and colorectal cancer incidence due to differential screening by family history may extend to future generations. If a screening test is effective at removing precursor lesions from the population, a person with a high underlying genetic risk of colorectal cancer who receives screening may avoid developing the disease. As a consequence of this primary prevention, the offspring of such screened individuals, who may have the same elevated genetic risk of cancer, will no longer have a recognized family history of cancer.
METHODS
To illustrate how the relationship between cancer and an observed family history of the disease may change due to screening utilization, we developed a model that estimates the risk of colorectal cancer relative to reported parental history of the disease in 3 consecutive generations. Model assumptions and definitions are outlined in eAppendix 1 (http://links.lww.com/EDE/A550). The population of generation i can be divided into 3 subgroups: 
Model in Generation 1
In the first generation, screening is not used and has not been previously used. Therefore, no one is incorrectly classified by family history (ie, N 01 (1) ϭ 0). In this generation, the relative risk (RR) of colorectal cancer comparing those with and those without an observed family history is set to 2.0.
Model in Generation 2
Screening is introduced in generation 2. Because screening was not used in generation 1, there is again no misclassification by family history (ie, N 01 (2) ϭ 0). Details of the model application in generation 2 are outlined in eAppendix 2 (http://links.lww.com/EDE/A550).
As screening is introduced, some colorectal cancers will be prevented in this second generation. Because the proportion of the population receiving screening is greater in those with an observed family history than in those without, the model predicts that the relative risk observed in generation 1 (RR ϭ 2.0) will be attenuated in generation 2. Furthermore, this attenuation will increase as screening efficacy improves.
Model in Generation 3
In the third generation, screening utilization is maintained in the population. Some will have parents with occult family history because screening in generation 2 prevented colorectal cancer from occurring (ie, N 01 (3) 0). Details of the model application in generation 3 are outlined in eAppendix 3 (http://links.lww.com/EDE/A550).
In calculating the relative risk with family history in generation 3, children of those in generation 2 who had colorectal cancer prevented by screening are now classified in the group without an observed family history (ie, N 01 ), despite a potentially increased underlying genetic risk for the disease. There is an attenuated relative risk in generation 3 associated with observed family history due to both the higher uptake of screening for those in generation 3 with an observed family history and also misclassification of those with an occult family history as lacking a family history of the disease (due to the introduction of screening in generation 2).
Scenarios for Model Simulation
We applied the model to scenarios of several colorectal cancer screening prevalences in those with an observed family history (ƒ 1 ) and those without (ƒ 0 ).
RESULTS
The Figure shows the attenuation of the relative risk with observed family history of colorectal cancer, given screening in the parent's generation. With an increasing difference in screening fraction between those with and those without family history (ie, moving from left to right along the x-axis, relative to a given point on the y-axis), the attenuation of relative risk for family history becomes more pronounced. Attenuation is also more marked with higher population levels of screening coverage, where the relative difference in screening for those with and those without a family history remains constant. Estimated relative risks with family history in generation 2 and 3 are provided in the Table for a select (1) is assumed to be the true relative risk between observed colorectal cancer family history and colorectal cancer incidence.
␥ indicates the proportion of colorectal cancers that can be prevented by screening; ƒ 1 , the prevalence of screening in individuals with an observed colorectal cancer family history; ƒ 0 , the prevalence of screening in individuals without an observed colorectal cancer family history; RR(i), relative risk in generation i ϭ 1, 2, or 3. series of possible screening scenarios. For example, with screening coverage of 70% in those with an observed family history and 30% in those without an observed family history, the relative risk for family history will fall from 2.00 in generation 1, to 1.23 in generation 2, to 1.17 in generation 3.
DISCUSSION
As colorectal cancer screening is more widely performed and precursor lesions are more often removed, more cases of colorectal cancer will be prevented. Because those with a family history of the disease are screened at a higher rate, their risk will be reduced even further.
As previously described, attenuation of the relative risk in generation 2 reflects the benefits of screening: persons with family history are more likely to receive screening and thus more likely to avoid cancer diagnosis through the detection and treatment of precancerous lesions. The attenuation of the relative risk in generation 3 similarly reflects differential screening by observed family history, but also reflects misclassification of occult family history in persons whose parents would have been diagnosed with colorectal cancer in the absence of screening in generation 2 (ie, N 01 (3)). As demonstrated in this simulation, many parents who would have developed colorectal cancer in the absence of screening remain cancer free because of screening. Because screening prevented the disease in parents, the offspring no longer have an observed family history of disease to report, despite any underlying inherited genetic risk or shared environmental risk factors for the disease that remain unchanged. Thus, with increased screening uptake, observed family history may no longer match true, inherited family risk (ie, what would have happened in the absence of screening), and observed family history will fail to emerge as a strong and consistent risk factor for developing colorectal cancer.
Our model is simplified in that it considers only cancer history in a person's parents. Although parental history is most often collected in epidemiologic studies, history among other relatives is also likely to be important. However, the overall principle would remain valid because colorectal cancer is avoided due to screening, a person's true risk profile may no longer match the observed family history of cancer. Our model also does not address a potential exaggeration of the association between observed family history and colorectal cancer; in the situation where screening is very effective and prevents most disease from occurring, cancers that occur despite screening may be more aggressive and associated with a strong, inherited family history genotype.
Ultimately, as screening utilization increases, the prevalence of risk factors for cancer and their association with disease may change over time. We have illustrated this potential effect using the example of differential colorectal screening uptake by observed family history of the disease.
Similarly, if other exposures are associated with greater screening, the relative risk for that exposure-disease relationship may change over time. This may also apply to other cancers, although with possibly different effects depending on the capacity of screening to identify and treat true precancerous lesions versus lesions with limited malignant potential.
